Introduction
A number of important human pathogens invade the body through mucosal surfaces. In these cases, the mucosal immune system acts as the first line of defense against infection [1] . Development of vaccines that stimulate the immune system on those mucosal surfaces is critical for generating immune protection against those mucosal pathogens [2] . A confounding feature of the mucosal immune system, however, is a well-developed immune tolerance mechanism [3] , which likely evolved to avoid the generation of unwarranted immune responses to commonly encountered environmental Ags [4] . As a consequence, it is difficult to evoke strong mucosal immune responses solely by administering Ag to a mucosal site. To overcome this immunological barrier, Ags are commonly administered in the presence of a strong mucosal adjuvant. Two of the earliest mucosal adjuvants described belong to the type I subfamily of heat-labile enterotoxins, which includes cholera toxin of Vibrio cholerae and LT (referred herein as LT-I) of Escherichia coli, and their respective non-toxic B subunits [5] [6] [7] [8] . Recently, the powerful mucosal adjuvant properties of a second subfamily of heat-labile enterotoxins were described. LT-IIa is a type II heat-labile enterotoxin of E. coli [5, 8] , which when delivered simultaneously with an Ag by the mucosal route (e.g., intranasal or oral), amplifies Ag-specific primary and memory immune responses on the mucosal surface and in the systemic circulation [9, 10] . Similar augmented Ag-specific immune responses were observed when Ags were mucosally delivered in the presence of LT-IIa-B
5
, the non-toxic B subunit of LT-IIa [8] . Understanding the mechanisms by which mucosal adjuvants trigger strong memory immune responses to coadministered Ags is critical for development of successful vaccines against serious human mucosal pathogens. In this study, we investigated the mucosal adjuvant properties of LT-IIa-B 5 using genome-wide gene expression profiling, specifically in regard to the responses to dendritic cells (DCs), a cell type that has been shown to react in vitro and in vivo to the pentamer [8, 11] . Using a mouse mucosal immunization model, we evaluated the effect of LT-IIa-B 5 on migration of DCs to the lymph nodes and changes in expression of the CC chemokine receptors CCR7, CCR1, CCR2, and CCR5 and of co-stimulatory molecules and inflammatory cytokines. Analysis of these DC-mediated changes will provide new insights into the underlying immune mechanisms that are augmented by LT-IIa-B 5 and suggest new strategies that can be employed to develop mucosal vaccines to enhance Ag-specific immune responses on mucosal surfaces.
Materials and Methods

Mice
Female wild-type and DO11.10 mice [12] expressing T cell receptors specific to the ovalbumin (OVA) epitope (323-339) on the BALB/c background were purchased from The Jackson Laboratory (USA). All mice were used at 6 to 8 weeks of age. Animal experiments were approved by the Institutional Animal Care and Use Committee at The University at Buffalo (IACUC No. MIC01010Y).
Cloning and Purification of LT-IIa-B
5
Methods for the cloning and purification of His-tagged LT-IIa-B 5 were reported previously [8] . In brief, the plasmid pHN1.1 encoding LT-IIa-B was extracted from the cells using isotonic shock and purified by nickel affinity chromatography (Qiagen, USA). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting using polyclonal antibodies against the LT-IIa holotoxin were used to confirm the homogeneity of the purified LT-IIa-B
. The purified protein was analyzed for endotoxin by use of an end-point quantitative Limulus amoebocyte lysate assay (Charles River Endosafe, USA). The level of endotoxin in the purified preparations of LT-IIa-B 5 was 0.003 ng/μg protein, which is considerably below the level required to evoke an immune response in cells.
Migration Assay
Mice were treated with 15 μl of phosphate-buffered saline (PBS) or 100 μg of OVA in PBS (Sigma-Aldrich, USA) in the presence or absence of 10 μg of LT-IIa-B
5
. The final volume was divided between both external nares. After 3 days, the cervical lymph nodes (CLN) were removed and digested for 1 h in PBS containing 1 mg/ml collagenase D and 0.5 mg/ml DNase I. Total cells from the CLN were resuspended in FACS buffer (PBS containing 2% bovine serum albumin) by forcing the tissue through a 40 μm nylon cell strainer (BD Biosciences, USA). Cells from the mouse CLN were stained with a phycoerythrin-conjugated anti-mouse CD11c antibody (clone N418; BioLegend, USA) and an allophycocyanin-conjugated anti-mouse I-A/I-E antibody (clone M5/114.15.2; BioLegend, USA) with an Fc-blocking anti-mouse CD16/32 antibody (clone 93; BioLegend, USA). The cells were then washed and resuspended in FACS buffer. The number of CD11c + MHCII + DCDC was determined using a FACSCalibur four-color flow cytometer (BD Biosciences, USA) with flow cytometry counting beads (Thermo Fisher Scientific, USA).
Generation of Bone Marrow-Derived DC
Cells from the bone marrow flushed from the femurs and tibiae of 6 to 8 weeks old BALB/c mice were cultured in 6-well plates at 1 × 10 6 cells/ml in complete RPMI-1640 (Mediatech, USA) that was supplemented with 10% fetal bovine serum, 50 μM 2-mercaptoethanol, 1% HEPES, 1% sodium pyruvate, 1% nonessential amino acids (Invitrogen, USA), 10 ng/ml recombinant murine IL-4 (eBioscience), and 20 ng/ml recombinant murine granulocyte macrophage-colony stimulating factor (BioLegend, USA). The culture medium was replaced on day 3 and the cells were used on day 6, at which point over 90% were CD11c + (data not shown). Non-adherent CD11c + DCs were sorted on day 6 using anti-CD11c-coated magnetic beads, according to the manufacturer's directions (Miltenyi Biotech, Germany). Sorted CD11c + DCs were used for subsequent experiments.
Microarray and Data Analysis
Purified DCs (5 × 10
6
) in 10 ml of complete RPMI culture medium were incubated for 6 h at 37°C with PBS alone (untreated) or PBS containing 1 μg/ml of LT-IIa-B
5
. Total RNA was isolated from the DCs using Trizol (Invitrogen, USA). Analyses were conducted using an Affymetrix whole-genome expression microarray (Mouse genome 430 2.0 array). Data were summarized and normalized with the robust multi-average method implemented in Affymetrix Expression Console software. The results of the gene-level robust multi-average analysis were exported and used for the differentially expressed gene analysis. Statistical significance of the expression data was determined using the local pooled error test and fold change, in which the null hypothesis was that no difference existed among groups. The false discovery rate was controlled by adjusting the p-values using the Benjamini-Hochberg algorithm. For a differentially expressed gene set, hierarchical cluster analysis was performed using complete linkage and Euclidean distance as a measure of similarity. Gene-enrichment and functional annotation analyses for the significant probe list were performed using DAVID (http://david.abcc.ncifcrf.gov/home.jsp). All data analyses and visualization of differentially expressed genes were conducted using R 3.0.2 software (http://www.r-project.org).
Statistical Analysis
Analysis of variance was used for multiple comparisons. Unpaired-t tests were performed to analyze differences between two groups. Statistical analyses were performed using the Prism software package (GraphPad Software, USA). Differences were considered significant at p ≤ 0.05.
Results
Gene Expression Profile of DCs Regulated by LT-IIa-B
5
, and between-Group Analysis of the Microarray Data
Transcriptional analyses were performed using 99% pure CD11c + DCs (data not shown) to investigate changes in the genome-wide transcription levels between untreated and LT-IIa-B
-treated cells. The analysis identified 732 genes that were upregulated by ≥2-fold and 1,028 genes that were downregulated by ≥2-fold in LT-IIa-B
-treated DCs in comparison to untreated DCs. To understand the biological significance of these microarray data, we further analyzed those differentially expressed genes using functional enrichment analysis with the DAVID database, a Gene Ontology (GO) software tool (http://david.abcc.ncifcrf. gov/home.jsp). Because GO (http://www.geneontology.org/) annotations are important for investigation of functional significance from large dataset, we followed these annotations based on the GO consortium (3) and found 101 significant GO terms, the majority of which were associated with triggering immune response and defense response. The top GO term was immune response. The 113 LT-IIa-B 5 -mediated differentially regulated genes associated with the immune response GO term are shown in Table 1 . Among 1,760 genes significantly differentially regulated in DCs by LT-IIa-B
, 79 immune response-associated genes (4.48% from total differentially regulated by LT-IIa-B
) were upregulated and 34 immune response-associated genes (1.9% from total differentially regulated by LT-IIa-B
) were downregulated (Figs. 1A and 1B) . Furthermore, in the top 10 GO terms, four terms (immune response, response to wounding, inflammatory response, cytokine-cytokine receptor interaction) were related with immune regulation directly (data not shown). These results strongly suggest , but not untreated DCs, transformed into a mature DC phenotype by significantly increasing the expression of CCR7, a critical chemokine receptor for homing to the lymph nodes [11, 13] ( Fig. 2A) . In addition, DCs activated with LT-IIa-B 5 showed reduced expression levels of CCR1, CCR2, and CCR5, which are inflammatory chemokine receptors that facilitate migration of inflammatory immune cells, such as T lymphocytes and monocytes, into inflamed peripheral tissues [14] . Downregulation of these inflammatory chemokine receptors and the subsequent upregulation of CCR7 likely induce migration of DCs into the draining lymph nodes.
The homing process of DCs after exposure to Ags in peripheral tissues is a critical step for triggering Ag-specific adaptive immune responses orchestrated by T lymphocytes, and is initiated by the migration of Ag-priming DCs into the lymph nodes. To confirm our hypothesis of an association between the selectively regulated expression pattern of chemokine receptors and homing to the draining lymph nodes by DCs, we investigated the number of DCs in the CLN after intranasal administration of LT-IIa-B (Fig. 2B) .
LT-IIa-B
-Mediated Transformation of DCs by Selectively Regulating Expression of Co-Stimulatory Molecules and Cytokines
Critical changes in the expression of relevant genes in immature bone marrow-derived DCs were observed upon treatment with LT-IIa-B
5
. In our previous study, we also found that CD40, CD80, and CD86 were increased in an in vivo mice model after intranasal administration of LT-IIa-B 5 [11] . Co-stimulatory molecules such as CD40, CD80, and CD86 that are required for robust Ag-priming of naïve and central memory T cells were significantly enhanced [15] .
Thus, we want to confirm expression of CD40, CD48, and CD86 in our microarray data. As a result, we found the similar results that CD40, CD80, and CD86 were increased in DCs treated with LT-IIa-B 5 (Fig. 3A) . In addition, changes in the expression levels of the intercellular adhesion molecules (ICAMs) of DCs were evident. Specifically, the transcriptional levels of ICAM1 were increased, while the levels of ICAM2 and ICAM4 were decreased in DCs activated by LT-IIa-B 5 (Fig. 3A) . Moreover, we found that another adhesion molecule, TGFβi, was significantly downregulated by DCs activated with LT-IIa-B 5 (Fig. 3A) . Thus, we found that LT-IIa-B elicited a dramatic increase in the transcription of numerous inflammatory cytokines, including tumor necrosis factoralpha (TNFα), IL-1α, IL-1β, IL-2, IL-6, and IL-12 (Fig. 3B) . In contrast, transcription levels of transforming growth factor-beta (TGFβ)1 and TGFβ2 were not significantly changed (Fig. 3B) . Furthermore, DCs activated with LT-IIa-B 5 reduced their sensitivity to the anti-inflammatory cytokine TGFβ by decreasing the expression of TGFβ receptors 1 and 2 (Fig. 3C) . Significantly increased transcription levels of chemokine genes CCL2, CCL3, CCL4, CXCL1, CXCL2, CXCL3, CXCL5 , CXCL9, CXCL10, and CXCL16 were also observed in our microarray (Fig. 3D) .
Discussion
Most pathogens invade the human body through mucosal tissues. Thus, there has been increasing efforts to develop vaccines that evoke strong pathogen-specific mucosal immune responses on the mucosal surfaces to interdict pathogens at an early stage of infection [16] [17] [18] .
In this study, we performed a genome-wide transcriptional profile analysis to investigate the mechanisms by which LT-IIa-B
5
, a potent mucosal adjuvant, regulates DCs, an immune cell type that orchestrates important cellular responses. Although several studies have described the properties by which LT-IIa-B 5 enhances mucosal immune responses to co-administered Ags [7, 16] , few studies have evaluated the molecular and genetic mechanisms that drive immune augmentation by LT-IIa-B
. Herein, we employed a genome-wide analysis to determine the transcriptional responses of DCs that were engendered by exposure to LT-IIa-B
. We found that LT-IIa-B -treated DCs using a GO software tool. This analysis revealed that 79 genes, 4.48% from total genes differentially regulated in DCs by LT-IIa-B
, were upregulated, and 34 genes, 1.9% from total genes differentially regulated in DCs by LT-IIa-B
, were downregulated, each of which is involved in immune response. Furthermore, we found that LT-IIa-B 5 enhanced the lymph node-homing capacity of DCs by selective regulation of chemokine receptors. Specifically, transcription of CCR7 was highly increased by treatment of DCs with LT-IIa-B
, while expression of genes encoding CCR1, CCR2, and CCR5 was decreased. These in vitro observations and their implications for adjuvant activity were supported by the in vivo migration assay. Indeed, after intranasal administration of LT-IIa-B
, the number of DCs in mice was increased dramatically in the proximal draining CLN. In our previous report [11] , we showed that enhanced migration of DCs into draining CLN after intranasal administration of LT-IIa-B 5 was dependent on CCR7, using CCR7 knockout mice, which did not show increased migration of DCs after administration of LT-IIa-B
. In this study, we suggest that those LT-IIa-B
-triggered migration of DCs was not mediated only by the increase of CCR7 on DCs, but also selective regulation of multiple chemokine receptors like CCR1, 2, 5 and adhesion molecules like ICAM1, 2, 4, and TGFβi. DCs exposed to LT-IIa-B . Transcription of ICAM1 was significantly increased, whereas the transcription of ICAM 2 and 4 was decreased. Markey et al. [19] reported that ICAM1 was a critical component for the immunological synapse between dendritic and T cells. Thus, we suggest that LT-IIa-B 5 can enhance the immunological synapse formation between dendritic and T cells via increased expression of ICAM1 to boost Ag-specific T cell activation. These findings suggested that ICAM1 might be a critical molecule for promoting strong T cell-DC synapse formation and subsequently boosting Ag-specific T cell activation. Such sophisticated regulation of multiple chemokine receptors and adhesion molecules of DCs might be required for their migration into draining lymph nodes after their exposure to LT-IIa-B
. Furthermore, the increased expression of pro- TNFα, IL-1α, IL-1β, IL-2,  IL-6, and IL-12, and chemokines including CCL2, CCL3,  CCL4, CXCL1, CXCL2, CXCL3, CXCL5, CXCL9, CXCL10 , and CXCL16 observed, in part, explains the strong adaptive immune responses that are driven by LT-IIa-B
inflammatory cytokines including
5
. In contrast, the transcription of the anti-inflammatory cytokines TGFβ1 and TGFβ2 by LT-IIa-B 5 was not changed (Fig. 3B) , indicating a directional activation or differentiation mechanism by LT-IIa-B in triggering the strong immune responses to co-administered Ags that have been observed in various studies [7, 11] .
Taken together, our results indicate that the adjuvant mechanism of LT-IIa-B 5 is likely a driving force for the differentiation of DCs into the morphotypes required to evoke strong immune responses. This conclusion is based on the capacity of LT-IIa-B 5 to upregulate the migration, cytokine expression, chemokine expression, and the sensitivity of DCs themselves to immunomodulatory mediators. Overall, the results of this transcriptional study revealed an important profile for the DC-mediated adjuvant mechanism triggered by LT-IIa-B
. Genome-wide analysis is a useful and powerful tool for revealing the potential mechanisms underlying the adjuvant properties of LT-IIa-B 5 and other mucosal adjuvants, and for suggesting avenues for productive experimentation to dissect these immune mechanisms. In conclusion, the current genome-wide analysis broadens our understanding of the immunological processes triggered by LT-IIa-B 5 and potentially other immunomodulatory molecules, which will likely facilitate development of better mucosal vaccines that incorporate these powerful adjuvants.
